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Abstract
Lindera obtusiloba is a medicinal herb traditionally used in Asia for improvement of blood circulation, treatment of
inflammation, and prevention of liver damage. A previous study has shown that an ethanolic extract of Lindera obtusiloba
stems (LOE) has vasoprotective and antihypertensive effects. The possibility that Lindera obtusiloba improves endothelial
function and metabolic parameters in type 2 diabetes mellitus (T2DM) remains to be examined. Therefore, the aim of the
present study was to determine the potential of LOE to prevent the development of an endothelial dysfunction, and
improve metabolic parameters including hyperglycemia, albuminuria and physical exercise capacity in db/db mice, an
experimental model of T2DM. The effect of LOE (100 mg/kg/day by gavage for 8 weeks) on these parameters was compared
to that of an oral antidiabetic drug, pioglitazone (30 mg/kg/day by gavage). Reduced blood glucose level, body weight and
albumin-creatinine ratio were observed in the group receiving LOE compared to the control db/db group. The LOE
treatment improved endothelium-dependent relaxations, abolished endothelium-dependent contractions to acetylcholine
in the aorta, and normalized the increased vascular oxidative stress and expression of NADPH oxidase, cyclooxygenases,
angiotensin II, angiotensin type 1 receptors and peroxynitrite and the decreased expression of endothelial NO synthase in
db/db mice. The angiotensin-converting enzyme (ACE) activity was reduced in the LOE group compared to that in the
control db/db group. LOE also inhibited the activity of purified ACE, COX-1 and COX-2 in a dose-dependent manner. In
addition, LOE improved physical exercise capacity. Thus, the present findings indicate that LOE has a beneficial effect on the
vascular system in db/db mice by improving endothelium-dependent relaxations and vascular oxidative stress most likely
by normalizing the angiotensin system, and also on metabolic parameters, and these effects are associated with an
enhanced physical exercise capacity.
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Introduction
The prevalence of type 2 diabetes mellitus (T2DM), which is
characterized by insulin resistance sometimes associated with
relative insulin deficiency, is continuously increasing in western-
ized societies due to the aging population, the increased prevalence
of obesity and sedentary lifestyles [1,2,3]. T2DM is a metabolic
disorder of multiple etiologies characterized by chronic hypergly-
cemia, which results in the development of diabetes-related
complications such as cardiovascular diseases, nephropathy,
neuropathy and retinopathy [4,5,6]. It has been estimated that
more than 80% of patients with T2DM have major cardiovascular
diseases such as coronary artery diseases, heart failure and
peripheral artery diseases [7,8,9].
An endothelial dysfunction characterized by blunted endo-
thelium-dependent vasorelaxation is observed early in the
development of diabetes mellitus and has been suggested to
be a key event in the initiation and development of both macro-
vascular and micro-vascular complications in T2DM [10,11,12].
Indeed, reduced flow-mediated dilation of the brachial artery
has been observed in clinical studies [13,14], and blunted
endothelium-dependent relaxations of isolated arteries in several
experimental models of T2DM such as the leptin receptor
deficient db/db mice, Goto-Kakizaki rats, Otsuka Long-Evans
Tokushima fatty rats, and Zucker diabetic fatty rats [12,15].
The characterization of the blunted endothelium-dependent
relaxations in T2DM has indicated the involvement of reduced
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nitric oxide (NO) and endothelium-dependent hyperpolarization
(EDH) components, two major endothelium-derived vasorelax-
ing mechanisms [16,17]. Moreover, the endothelial dysfunction
is related to increased oxidative stress in the arterial wall
involving increased formation of superoxide anion and hydrogen
peroxide, predominantly due to an up-regulation of NADPH
oxidase throughout the arterial wall, and possibly also to an
uncoupling of endothelial NO synthase (eNOS) [18]. Reactive
oxygen species (ROS) such as superoxide anions may reduce the
NO bioavailability by chemically reacting with NO to generate
peroxynitrite, but also by reducing the bioavailability of
tetrahydrobiopterin (BH4), an essential cofactor of eNOS
[19,20]. In addition, oxidative stress has also been associated
with blunted EDH-mediated relaxations, at least in part, by
reducing the expression of both small and intermediate
conductance calcium-dependent potassium channels (SKCa and
IKCa, respectively) [21]. The endothelial dysfunction in T2DM
has also been associated with the induction of endothelium-
dependent contractile responses involving cyclooxygenase-de-
rived metabolites of arachidonic acid (AA) acting on TP
receptors to contract the vascular smooth muscle [22].
Several lines of evidence suggest that the angiotensin system
contributes to the impaired endothelial function in T2DM.
Indeed, angiotensin-converting enzyme (ACE) inhibitors and
angiotensin II (Ang II) receptor type I blockers prevented
endothelial dysfunction in diabetic animals and humans [23,24].
Moreover, Ang II is a potent inducer of endothelial dysfunction
and NADPH oxidase-derived vascular oxidative stress [23,25].
Stems of Lindera obtusiloba have been used to treat bruises, blood
stasis, and swelling in the Korean traditional medicine [26].
Moreover, our previous study has indicated that an ethanolic
extract of Lindera obtusiloba stems (LOE) at a dose of 100 mg/kg/
day prevented endothelial dysfunction and hypertension induced
by the chronic infusion of Ang II to rats, in part, by normalizing
the NADPH oxidase-dependent vascular oxidative stress [27].
Therefore, the aim of the present study was to determine whether
LOE prevents endothelial dysfunction in an experimental model
of T2DM, the db/db mice, through inhibition of oxidative stress
and the angiotensin system.
Results
LOE Improves Clinical Parameters in db/db Mice
As expected, the weight gain increased to a greater extent in the
db/db group compared to the db/+ group from week 6 until week
14 (Table 1). The LOE treatment significantly reduced the weight
gain in the db/db group by about 18.667% whereas the weight
gain was more pronounced in the pioglitazone group (the increase
amounted to about 25.664.5%, Table 1). The intake of food,
which was determined every week, was significantly greater in the
db/db group compared to that in the db/+ group, and this effect
was affected neither by the pioglitazone treatment nor the LOE
treatment (Table 1). At week 14, the liver weight in the db/db
group was significantly greater than that of the db/+ group
(Table 1). The LOE treatment reduced slightly but not signifi-
cantly the liver weight by 15.463.8% whereas the pioglitazone
treatment increased it significantly by 46.267.8% (Table 1). The
heart weight was similar in the db/+ group and the db/db group,
and it was not affected by the LOE treatment but significantly
increased by the pioglitazone treatment by about 2569.9%
(Table 1). The kidney weight was similar in the 4 groups tested
(data not shown).
LOE Improves Metabolic Parameters in db/db Mice
Both non-fasting and fasting blood glucose levels increased
markedly from week 6 until week 14 in the db/db group whereas
they remained unchanged in the db/+ group (Fig. 1 A and B).
LOE treatment significantly reduced non-fasting blood glucose
levels from week 10 until week 12, and also of fasting blood glucose
levels from week 9 until week 14 in the db/db group (Fig. 1 A and
B). In contrast, pioglitazone abolished the increase in both the
non-fasting and fasting blood glucose levels (Fig. 1 A and B).
The determination of metabolic parameters in plasma indicated
that GOT and GPT levels were similar in db/+ mice and db/db
mice, and that the LOE treatment did not affect both parameters
whereas the GPT level but not the GOT level was significantly
increased by the pioglitazone treatment (the increase amounted to
480689.2% compared to that of the db/db group, Table 2).
Analysis of the lipid profile showed that the CHO, TG and HDL
levels were significantly increased in db/db mice compared to
those in db/+ mice whereas the LDL levels were similar (Table 2).
The LOE treatment did not significantly affect the CHO, HDL
and LDL levels but significantly reduced that of TG by
65.569.1% in db/db mice (Table 2). The pioglitazone treatment
significantly increased the CHO level by 69.1618.3%, affected
minimally the LDL and the HDL level, and decreased markedly
that of TG by 114.567.5% in db/db mice (Table 2).
LOE Prevents Albuminuria in db/db Mice
As expected, the db/db group had markedly increased 24-h
urinary volume compared to that of the db/+ group, this effect
was not affected by the LOE treatment but abolished by the
pioglitazone treatment (Table 3). The albumin-creatinine ratio
(ACR, an indicator of renal function) was markedly increased by
about 335.266.1% in the db/db group compared to the db/+
group, and this effect was significantly reduced by the LOE
treatment by about 36.260.5% but not by the pioglitazone
treatment (Table 3).
LOE Improves Endothelium-dependent Relaxations and
Prevents Endothelium-dependent Contractions in db/db
Mice
Ach caused concentration-dependent relaxations in aortic rings,
which reached about 65.5% at 10 mM in the db/+ group but only
about 21.7% in the db/db group (Fig. 2A). Both the pioglitazone
and the LOE treatment improved markedly endothelium-depen-
dent relaxations to Ach in the db/db group (Fig. 2A; maximal
relaxations were 51.1% and 72.7%, respectively). In the presence
Table 1. Effect of LOE and pioglitazone on body weight,
organ weight and food intake in db/db mice.
db/+ db/db db/db+Pio db/db+LOE
Body weight (6 weeks), g 24.060.3 30.560.7* 29.660.7* 30.560.6*
Body weight (14 weeks), g 27.360.4 51.561.1* 57.761.1*,# 47.061.7*,#
Liver weight, g 1.460.03 2.660.1* 3.860.2*,# 2.260.1*
Heart weight, mg 14163 14265 178614* 13266
Food intake (14 weeks),
g/24 h
4.460.5 6.660.5* 5.860.3* 5.860.4*
Values are shown as means 6 S.E.M. (n = 13–14).
*P,0.05 indicates a significant difference versus the db/+ group,
#P,0.05 indicates a significant difference between db/db group and db/
db+Pio group or db/db+LOE group.
doi:10.1371/journal.pone.0065227.t001
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of Nv-nitro-L-arginine to prevent the endothelial formation of
NO, Ach at 10 mM caused small but significant contractions in
aortic rings with endothelium in the db/db group but not in the
db/+ group, the db/db+Pio group and the db/db+LOE group
(Fig. 2B). The NO donor SNP caused similar relaxations in aortic
rings in all four groups (Fig. 2C). In addition, indomethacin, an
inhibitor of cyclooxygenases, slightly but significantly improved
relaxations to Ach in the db/+, the db/db and the db/db+Pio
groups whereas no such effect was observed in the db/db+LOE
group (Fig. 3A). The possibility that LOE is able to inhibit COX-1
and COX-2 activity was assessed using purified enzymes. As
shown in Figure 3B, LOE inhibited in a concentration-dependent
manner purified COX-1 and COX-2 with IC50 of 85.461.38 and
104.761.12 mg/ml, respectively.
LOE Decreases Vascular Oxidative Stress and the Up-
regulation of NADPH Oxidase Subunits and
Cyclooxygenases in db/db Mice
A marked increase of the fluorescence ethidium signal was
observed throughout the aortic wall in the db/db group compared to
the db/+ group (the increase amounted to 238.7629.7%) indicating
an increased level of oxidative stress (Fig. 4A). This effect was
associated with an enhanced expression of the NADPH oxidase
subunits NOX-1 (249.7651.6%) and p47phox (249.9621.2%), and
peroxynitrite as assessed by nitrotyrosine fluorescence
(399.4660.3%, Fig. 4C, D and E). In the db/db group, an increased
vascular expression level of COX-2 (329.5646.0%, Fig. 4G) was
observed whereas that of COX-1 was similar (Fig. 4F) and that of
eNOS was reduced compared to the db/+ group (46.4615.9%,
Fig. 4B). The LOE treatment significantly decreased the formation
of ROS and peroxynitrite, and the expression of NOX-1, p47phox,
and COX-2, up-regulated that of eNOS, and did not affect that of
COX-1 in the db/db group (Fig. 4). Compared to db/db+Pio group,
the LOE treatment significantly decreased the formation of ROS
and peroxynitrite, and the expression of NOX-1, COX-1, and
COX-2, and it up-regulated that of eNOS (Fig. 4). In contrast, the
pioglitazone treatment did not affect the increased level of oxidative
stress, peroxynitrite, NOX-1, p47phox and COX-2 in aortic
sections of the db/db group but it markedly increased the expression
level of COX-1, and slightly but not significantly that of eNOS
(Fig. 4).
LOE Reduces the Vascular Angiotensin System in db/db
Mice
Since previous studies have shown that LOE prevented Ang II-
induced hypertension and endothelial dysfunction in rats [27], and
Figure 1. LOE and pioglitazone treatments improve blood
glucose levels in db/db mice. (A) Non-fasting and (B) fasting blood
glucose levels from week 6 until week 14. All groups were fasted for 4 h
before blood samples were taken. Values are shown as means 6 S.E.M.
(n = 13–14). *P,0.05 indicates a significant difference versus db/db
group.
doi:10.1371/journal.pone.0065227.g001
Table 2. Effect of LOE and pioglitazone on metabolic
parameters in plasma of db/db mice.
db/+ db/db db/db+Pio db/db+LOE
GOT, mg/dl 145.0613.1 160.2617.4 205.1614.6* 197.1615.4
GPT, mg/dl 37.969.8 78.869.8 275.1636.5*,# 77.1612.7
CHO, mg/dl 56.063.1 89.463.5* 112.566.1*,# 82.064.8*
TG, mg/dl 58.067.2 191.4626.0* 38.7610.0*,# 104.0612.2*,#
HDL, mg/dl 30.562.5 49.661.4* 56.562.6* 46.363.4*
LDL, mg/dl 4.460.6 5.360.6 7.060.7* 4.960.4
Values are shown as means 6 S.E.M. (n = 13–14).
*P,0.05 indicates a significant difference versus the db/+ group,
#P,0.05 indicates a significant difference between db/db group and db/
db+Pio group or db/db+LOE group.
doi:10.1371/journal.pone.0065227.t002
Table 3. Effect of LOE and pioglitazone on urinary volume
and renal function in db/db mice.
db/+ db/db db/db+Pio db/db+LOE
Urinary volume, ml 0.8460.13 8.3161.66* 0.7960.13# 8.4561.25*
ACR, mg/g 22.4460.60 75.2361.38* 69.9060.58* 48.0060.46*,#
ACR: albumin-creatinine ratio. Values are shown as means 6 S.E.M. (n = 13–14).
*P,0.05 indicates a significant difference versus the db/+ group,
#P,0.05 indicates a significant difference between db/db group and db/
db+Pio group or db/db+LOE group.
doi:10.1371/journal.pone.0065227.t003
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that increased levels of Ang II and its major receptor, Ang II type 1
receptor (AT1R), are observed in aortic sections of db/db mice
[28], the possibility that LOE affects the local angiotensin system
was assessed. The expression level of Ang II and AT1R in aortic
sections was significantly increased to about 305.0683.2% and
245.7657.2%, respectively, in the db/db group compared to the
db/+ group (Fig. 5A and 5B). The pioglitazone treatment did not
affect Ang II and AT1R levels whereas the LOE treatment
markedly reduced those to 90.9633.0% and 85.6621.6%,
respectively (Fig. 5A and 5B). The possibility that the LOE
treatment affects the ACE activity was assessed in the plasma. An
increased ACE activity was observed in the db/db group
compared to the db/+ group (44.763.9 and 2960.9 U/100 ml,
respectively), and the LOE treatment abolished the ACE activity
(2263.0 U/100 ml) whereas the pioglitazone treatment
(36.765.8 U/100 ml) was without effect (Fig. 6A). In addition,
LOE inhibited the enzymatic activity of a purified preparation of
porcine ACE in a concentration-dependent with an IC50 of
123.3 mg/ml (Fig. 6B).
LOE Improves the Physical Performance of db/db Mice
A severely impaired physical exercise performance is often
observed in experimental models of obesity including the db/db
mice [29]. Therefore, experiments were performed to determine
whether the LOE treatment improves the physical exercise
capacity as assessed by the time and distance to exhaustion using
a treadmill. The db/db group showed a markedly impaired
physical exercise capacity (the time to exhaustion was reduced by
69.0% and the distance by 85.6% compared to the db/+ group,
Fig. 7A and 7B). The impaired responses were not affected by the
pioglitazone treatment but slightly but significantly improved by
the LOE treatment by about 6.3% and 5.1% compared to the db/
db group, respectively (Fig. 7A and 7B).
Discussion
The major findings of the present study indicate that chronic
intake of LOE by db/db mice improved the endothelial
dysfunction and the excessive vascular oxidative stress most likely
by normalizing the angiotensin system, and also several metabolic
parameters including hyperglycemia; all these effects were
associated with an improved physical exercise performance.
In T2DM, a disorder characterized by hyperglycemia and
insulin resistance, the development of an endothelial dysfunction is
often an early marker, which has gained interest since it is thought
to promote the development of diabetic microvascular and
macrovascular complications such as cardiovascular diseases and
retinopathy [30]. Thus, the search for novel treatments capable to
improve, besides hyperglycemia, the endothelial function is one of
the most promising goals to prevent diabetic vascular complica-
tions [31]. Previous studies have indicated that several polyphenol-
rich natural products are able to induce endothelium-dependent
relaxations by increasing the endothelial formation of major
vasoprotective factors such as NO and EDH, and also to prevent
and/or improve an established endothelial dysfunction in several
types of cardiovascular diseases such as hypertension
[32,33,34,35,36]. In addition, our previous investigations have
indicated that LOE is a potent inducer of NO-mediated
relaxations in aortic rings and stimulator of the PI3-kinase/Akt-
dependent phosphorylation of eNOS at the activator site Ser 1177
and, also, that LOE prevented the angiotensin II-induced
hypertension and endothelial dysfunction in rats [27]. The present
findings indicate that chronic administration of LOE to db/db
mice, an experimental model of T2DM, fully restored the severely
blunted endothelium-dependent relaxations to Ach in aortic rings
as well as improved partially hyperglycemia. In addition, since the
LOE treatment affected minimally relaxations induced by the NO
donor, SNP, and the endothelium-dependent relaxation to Ach in
aortic rings is abolished by Nv-nitro-L-arginine, an inhibitor of
Figure 2. LOE and pioglitazone treatments improve endothe-
lium-dependent relaxations and reduce endothelium-depen-
dent contractile responses to acetylcholine in aortic rings of
db/db mice. (A) Concentration-relaxation curves to Ach in aortic rings
with endothelium, (B) concentration-contraction curves to Ach in the
presence of Nw-nitro L-arginine (an inhibitor of eNOS) in rings with
endothelium, and (C) concentration-relaxation curves to sodium
nitroprusside (a NO donor) in rings with endothelium in the presence
of Nw-nitro L-arginine and indomethacin to avoid the formation of
endothelium-derived vasoactive NO and prostanoids, respectively.
Values are shown as means 6 S.E.M. (n = 5–6). *P,0.05 indicates a
significant difference between db/+ group versus db/db group, db/
db+Pio group or db/db+LOE group, and { db/db+Pio group versus db/
db+LOE group.pone.0065227.g003.tif
doi:10.1371/journal.pone.0065227.g002
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eNOS (data not shown), the beneficial effect of the LOE treatment
can be attributed to an improved endothelial NO-mediated
response rather than an improved cyclic GMP-dependent relaxing
pathway in the vascular smooth muscle. Interestingly, the oral
anti-diabetic drug, pioglitazone, normalized blood glucose levels in
db/db mice and it also improved the endothelial dysfunction. In
Figure 3. LOE inhibits the activity of cyclooxygenases. (A) Cyclooxygenase-derived vasoactive prostanoids blunt endothelium-dependent
relaxations to Ach in aortic rings of the db/+, db/db and db/db+Pio groups but not in the db/db+LOE group. Concentration-dependent relaxations
induced by Ach in aortic rings with endothelium in the absence and presence of indomethacin (an inhibitor of cyclooxygenases). Values are shown as
means 6 S.E.M. (n = 5–7). *P,0.05 indicates a significant difference versus the respective control. (B) LOE inhibits COX-1 and COX-2 activity in vitro in
a concentration-dependent manner. Values are shown as means 6 S.D. (duplicate determinations).
doi:10.1371/journal.pone.0065227.g003
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addition, the endothelial dysfunction in aortic rings of db/db mice
involves also the induction of small but significant endothelium-
dependent contractile responses to Ach, which were prevented by
both the LOE and the pioglitazone treatments. Moreover,
vasoconstrictor prostanoids also seem to blunt the Ach-induced
relaxations in both the db/+ and the db/db group since these
responses were potentiated by the cyclooxygense inhibitor,
indomethacin. Although a similar potentiating effect was observed
in the pioglitazone-treated group, no such effect was observed in
the LOE-treated group suggesting that LOE might inhibit
cyclooxygenases. Indeed, the in vitro determination of cyclooxy-
genase activity indicated that LOE inhibited the enzymatic activity
of both COX-1 and COX-2 in a similar manner.
Numerous studies have indicated that diabetes mellitus and
hyperglycemia are associated with an excessive vascular formation
of ROS, which largely accounts for the impaired endothelial NO
component due to the fact that NO can chemically react with
superoxide anions leading to the subsequent formation of
peroxynitrite but possibly also by oxidizing BH4, an essential
cofactor of eNOS leading to eNOS uncoupling [37]. Indeed,
vitamin C has been shown to correct endothelial dysfunction in
patients with either type 1 diabetes mellitus (T1DM) or T2DM
[38,39,40], and also in several animal models of diabetes mellitus
such as a streptozotocin-induced model [41,42]. Moreover, oral
glucose loading in healthy subjects without diabetes mellitus
caused an acute and transient decrease of flow-mediated dilation,
which was prevented by the vitamins C and E [43]. Several
vascular sources of ROS have been involved in the diabetes-
associated vascular oxidative stress including the NADPH oxidase,
uncoupled eNOS, xanthine oxidase and mitochondrial dysfunc-
tion [18,44]. Consistent with these previous findings, an increased
level of vascular oxidative stress was observed in db/db mice as
indicated by the marked ethidium staining throughout the arterial
wall, and the increased peroxynitrite, which was predominantly
observed at the luminal surface in the aorta of db/db mice. A
major role for the NADPH oxidase among several sources of ROS
in the arterial well is supported by the fact that an increased
expression of both NADPH oxidase subunits NOX-1 and
p47phox is observed throughout the arterial wall of db/db mice.
The beneficial effect of the LOE treatment on the endothelium-
dependent NO-mediated relaxation most likely involves its ability
to normalize vascular oxidative stress, in part, by normalizing the
expression of NADPH oxidase but also by restoring the blunted
eNOS expression in db/db mice. In several previous studies,
polyphenols have been shown to improve in part vascular
oxidative stress due to their direct antioxidant properties, their
ability to inhibit NADPH oxidase activity [45], and possibly also to
the induction of changes in the expression pattern of endogenous
pro-oxidant and anti-oxidant enzymes in the arterial wall
[46,47,48]. An improved vascular oxidative stress and endotheli-
um-dependent NO-mediated relaxation in response to polyphe-
nol-rich products has also been observed in several experimental
models of diabetes mellitus and vascular diseases including
hypertension and ageing [27,32,49,50]. Such a combination of
effects most likely accounts for the effectiveness of the LOE
treatment to restore a normal endothelial function and vascular
oxidative stress level despite the persistent hyperglycemia in db/db
mice. In addition, the endothelial dysfunction in db/db mice
appears to involve, besides oxidative stress, also several additional
key mechanisms since normalization of the hyperglycemia by the
pioglitazone treatment improved endothelial dysfunction despite
not affecting vascular oxidative stress.
Numerous studies have shown that in addition to hyperglyce-
mia, dyslipidemia and chronic inflammation of the arterial wall
are often observed in T2DM and are thought to contribute to its
progression and vascular complications [31,51]. Indeed, an
elevation of the triglyceride-rich lipoproteins level is likely to
promote the formation of non-esterified fatty acids (NEFA) and the
up-regulation of NADPH oxidase via activation of lectin-type
oxidized LDL receptor 1, and an elevation of the low-density
lipoprotein (LDL) level, which will result in the accumulation of
lipids into macrophages and, hence, plaque growth [31].
Moreover, numerous studies have shown that both hypertriglyc-
eridemia and hypercholesterolemia trigger the development of an
endothelial dysfunction associated with vascular oxidative stress
[52,53,54]. In the present study, an increased TG level was
observed in the db/db group compared to the db/+ group, which
was significantly reduced by both the LOE and the pioglitazone
treatments. In addition, although the db/db group had similar
LDL levels as the db/+ group, the pioglitazone treatment induced
a significant increase in LDL levels whereas the LOE treatment
was without effect. The possibility that the pioglitazone-induced
upregulation of LDL levels might counteract the beneficial effect
of the glitazone on the endothelial function remains to be studied.
The fact that both ACE inhibitors and AT1R blockers
prevented the endothelial dysfunction in diabetic animals and
humans indicates a determinant role of the angiotensin system
[23,24]. Moreover, an age-related increase in blood pressure has
been observed in db/db mice, which was reduced by an AT1
receptor antagonist [55]. Therefore, the possibility that the LOE
and/or the pioglitazone treatments improve the angiotensin
system was evaluated by determining the expression level of
several members of the angiotensin system including Ang II,
AT1R, and ACE activity in the arterial wall. Significantly
increased expression levels of both Ang II and AT1R were
observed throughout the arterial wall in the db/db group possibly
reflecting the higher ACE activity. The LOE treatment normal-
ized all these responses whereas the pioglitazone treatment was
without effect. In addition, LOE inhibited strongly partially
purified ACE with an IC50 of 123.3 mg/ml. Altogether, these
findings indicate that the inhibitory effect of LOE on the
angiotensin system is likely to contribute to its beneficial effect
on the endothelial dysfunction and vascular oxidative stress.
In order to better evaluate the potential beneficial effect of the
LOE treatment on T2DM, changes of body weight, food intake,
tissue weight, renal function, urinary volume and physical exercise
capacity were also determined throughout this study. As expected,
a pronounced increase in body weight was observed in the db/db
mice compared to the db/+ mice; this effect was partially reduced
by the LOE treatment possibly due to its ability to inhibit
adipogenesis via a sustained Wnt signaling [56]. In contrast, the
pioglitazone treatment increased body weight in the db/db group;
Figure 4. Effect of LOE and pioglitazone treatments on vascular oxidative stress, and the expression of eNOS, NADPH oxidase
subunits (NOX-1 and p47phox) and cyclooxygenases (COX-1 and COX-2) in aortic sections of db/db mice. The formation of reactive
oxygen species (ROS) was determined using the redox-sensitive probe dihydroethidine, and the expression of target proteins by immunofluorescent
staining. Top: representative immunofluorescent staining; bottom: corresponding cumulative data. The lumen is on the right side of each image, and
the scale bar corresponds to 50 mm. Values are shown as means 6 S.E.M. (n = 6–7). *P,0.05 indicates a significant difference between db/+ group
versus db/db group, db/db+Pio group or db/db+LOE group, {db/db group versus db/db+Pio group or db/db+LOE group, and #db/db+Pio group
versus db/db+LOE group.
doi:10.1371/journal.pone.0065227.g004
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Figure 5. Effect of LOE and pioglitazone treatments on the expression of angiotensin II (Ang II) and angiotensin II type 1 receptors
(AT1R) in aortic sections of db/db mice. The expression of Ang II and AT1R was assessed by immunofluorescent staining. Top: representative
immunofluorescent staining; bottom: corresponding cumulative data. The lumen is on the right side of each image, and the scale bar corresponds to
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such an effect is also often observed in treated diabetic animals and
humans [57,58]. In addition, db/db mice had an increased liver
weight reflecting most likely a fatty liver due to obesity whereas the
heart weight was normal. The LOE treatment did affect neither
the liver weight nor the heart weight whereas both were
significantly increased by the pioglitazone treatment.
The development of diabetes mellitus is often associated with
the induction of renal dysfunction. Indeed, diabetic nephropathy is
a major end-stage renal disease in USA, Europe and Japan [59].
Clinically, diabetic nephropathy can be diagnosed by albuminuria,
which can be identified by ACR [60]. Therefore, the albumin and
creatinine content, and the urinary volume of db/db mice were
determined. As expected, both the ACR and the urinary volume
were markedly increased in the db/db group. The LOE treatment
significantly improved the ACR suggesting an improvement of the
renal function in diabetic mice whereas no such effect was
observed with the pioglitazone treatment.
Physical exercise is generally recommended for the treatment of
T2DM because of its benefits on blood glucose control, insulin
tissue sensitivity and weight management despite the fact that their
exercise capacity is often impaired [61]. Therefore, the possibility
that the LOE treatment might affect the physical exercise
performance of db/db mice was determined using a treadmill.
The exercise capacity of db/db mice, as assessed by the time to
exhaustion and distance, was markedly lower than that of the db/
+ mice, and both parameters were slightly but significantly
increased by the LOE treatment but not by the pioglitazone
treatment. The enhanced exercise capacity in the LOE-treated
group most likely results from an improved metabolic state with a
reduced body weight, improved blood glucose control and
dyslipidemia, and an improved endothelial dysfunction and,
hence, blood flow.
Altogether, the present findings indicate that LOE has a
beneficial effect on T2DM targeting not only metabolic param-
eters such as hyperglycemia and dyslipidemia but also the
endothelial dysfunction and vascular oxidative stress most likely
by normalizing the angiotensin system. They further suggest that
LOE might be of interest to prevent the development of micro and
macrovascular complications in T2DM by improving the endo-
thelial control of vascular tone and, hence, blood flow.
Materials and Methods
Ethics Statement
This study conforms to the Guide of Care and the Use of
laboratory Animals published by the US National Institutes of
Health (NIH publication No. 85–23, revised 1996) and the present
protocol was approved by the local ethics committee (Comite´
Re´gional d’Ethique en Matie`re d’Expe´rimentation Animale,
approval AL/01/09/09/05).
Plant Extract and Standardization
The preparation of the extract of L. obtusiloba was prepared and
standardized as described previously [27]. The dried stems of L.
obtusiloba were collected in the vicinity of Hongcheon and were
bought from Yakcho119 (Hongcheon, Republic of Korea). The
voucher specimen (no. YJP-14) was deposited at the Herbarium of
Korea Institute of Science and Technology (KIST, Gangneung,
Kangwon-Do, Republic of Korea). L. obtusiloba was identified by
Dr. Sang Hoon Jung (KIST, Gangneung, Kangwon-Do, Republic
of Korea). Dried small branches were cut into small pieces and
grounded into powder. The L. obtusiloba powder (15.8 kg) was
extracted 4 times with 111 l of 50% aqueous ethanol (v/v) for 4 h
at 70uC. The resultant was then evaporated to dryness under
vacuum to produce 1.1 kg of a brown powder (yield of 7.0%). The
concentration of polyphenols in the LOE extract was determined
by the Folin-Ciocalteau assay and amounted to approximately
23.7% expressed as (2)-epicatechin equivalents. For HPLC
analysis, 10 ml of LOE (10 mg/ml solubilized in 50% aqueous
methanol) were injected into an Agilent 1200 series HPLC system.
Separation was carried out using a 4.66250-mm C18 reverse-
phase column (Shiseido) maintained at 35uC and eluted at a flow
50 mm. Values are shown as means6 S.E.M. (n = 6–7). *P,0.05 indicates a significant difference between db/+ group versus db/db group, db/db+Pio
group or db/db+LOE group, {db/db group versus db/db+Pio group or db/db+LOE group, and #db/db+Pio group versus db/db+LOE group.
doi:10.1371/journal.pone.0065227.g005
Figure 6. LOE reduces plasma angiotensin converting enzyme (ACE) activity in db/db mice (A), and inhibits the activity of purified
ACE (B). Values are shown as means 6 S.E.M. n = 6–7 (A) and 3 (B). *P,0.05 indicates a significant difference between db/+ group versus db/db
group, db/db+Pio group or db/db+LOE group, {db/db group versus db/db+Pio group or db/db+LOE group, and #db/db+Pio group versus db/
db+LOE group.
doi:10.1371/journal.pone.0065227.g006
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rate of 1.0 ml/min using a mobile phase of 17% aqueous
acetonitrile acidified with 0.1% trifluoroacetic acid. Chromato-
graphic profiles were recorded at 254 nm. In order to identify the
chemical structure of each peak, the ethanolic extract of L.
obtusiloba was subjected to preparative RP-HPLC using a 250620-
mm i.d. 4-mm HiQSil column (KYA TECH) eluted with 17%
aqueous acetonitrile to provide five major flavonoids. The
chemical structure of the flavonoid compounds was elucidated
by spectral analysis and direct comparison with authentic
compounds. The identified compounds included hyperin, iso-
quercitrin, guaijaverin, avicularin, and quercitrin [27].
Animal Treatments
For the present study, 14 male C57BL/KsJ Rj-db (db/+ mice, 5
week-old, 19–20 g) and 42 male C57BL/KsJ@Rj-db (db/db mice,
5 week-old, 20–22 g) were purchased from Elevage Janvier (Le
Genest-Saint-Isle, France). db/+ mice were assigned into one
group, and db/db mice were randomly assigned into three groups
of 14 mice. Mice were housed in colony cages under standard
laboratory conditions (12:12 h light/dark cycle) and had free
access to standard commercial diet and water. From week 6 until
week 14, the groups of db/db mice received by daily gavage either
vehicle (db/db group, 0.5% carboxymethylcellulose in 0.9% NaCl
solution), LOE (db/db+LOE group, 100 mg/kg/day), or piogli-
tazone (db/db+Pio group, 30 mg/kg/day, DAEBONG LS., Ltd.,
Korea). The control group included 14 db/+mice, which received
the vehicle. LOE at a dose of 100 mg/kg/day has previously been
shown to prevent angiotensin II-induced hypertension and
endothelial dysfunction in rats [27], and pioglitazone at 30 mg/
kg/day to preserve ß-cell mass in db/db mice [62].
Measurement of Metabolic Parameters
From week 6 until week 14, non-fasting and fasting blood
glucose levels were determined once a week using the Accu-ChekH
Go (Roche Diagnostics, Indianapolis, IN, USA). Fasting blood
glucose levels were determined 4 h after removing food. Food
intake and body weight were also measured weekly. At week 14,
mice were sacrificed, and organs were excised and their weight
determined. Blood was collected directly from the heart in the
presence of the anti-coagulant sodium heparinate and, thereafter,
plasma was prepared and stored in aliquots at270uC before being
tested. Glutamic-oxaloacetic transaminase (GOT), glutamic-pyru-
vic transaminase (GPT), triglyceride (TG), total cholesterol
(CHO), high-density lipoprotein (HDL), low-density lipoprotein
(LDL) levels in plasma were determined using the clinical
biochemistry analyzer Hitachi 7020 (Hitachi, Japan).
Measurement of Urine Parameters
One week before sacrifice, mice were placed in metabolic cages
for 24 h and thereafter, urine was collected for a 24-h period.
Thereafter, urine samples were stored at 270uC before being
analyzed. The albumin-creatinine ratio (ACR) in urine was
measured by ELISA kits (Ref 50200, CellTrend, Germany).
Vascular Reactivity Studies
The aorta was cleaned of connective tissue and cut into rings (2–
3 mm in length). Rings were suspended in organ baths containing
oxygenated (95% O2, 5% CO2) Krebs bicarbonate solution (in
mM: NaCl 119, KCl 4.7, KH2PO4 1.18, MgSO4 1.18, CaCl2
1.25, NaHCO3 25, and D-glucose 11, pH 7.4, 37uC) for the
determination of changes in isometric tension as described
previously [27]. Briefly, rings were stretched step by step until
the optimal resting tension of 1 g was reached and, then, were
allowed to equilibrate for at least 60 min. After the equilibration
period, the rings were exposed to Krebs bicarbonate solution
containing high concentration of potassium (80 mM) until
reproducible contractile responses were obtained. Thereafter,
rings were contracted with phenylephrine (PE, 1 mM) to approx-
imately 80% of the maximal contraction by the high potassium
solution. After washout and a further 30-min equilibration period,
rings were again contracted with PE before the construction of a
concentration-relaxation curve to either acetylcholine (Ach) or
sodium nitroprusside (SNP, an exogenous NO donor). In some
experiments, rings were exposed to an inhibitor for 30 min before
being contracted with PE. Relaxations were expressed as the
percentage of the reversal of the contraction induced by PE. For
the construction of the concentration-contraction curve to Ach,
rings with endothelium were exposed to Nw-nitro-L-arginine (L-
NA, 100 mM) for 30 min and then contracted to approximately
10% with PE (100 nM).
Figure 7. LOE but not pioglitazone improves slightly but significantly the physical exercise capacity of db/db mice. The physical
performance was assessed using a treadmill. (A) Time to exhaustion, (B) maximal distance run before exhaustion. Values are shown as means6 S.E.M.
(n = 13–14). *P,0.05 indicates a significant difference versus db/db group.
doi:10.1371/journal.pone.0065227.g007
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Determination of Vascular Reactive Oxygen Species
Formation
The oxidative fluorescent dye dihydroethidium (DHE, Invitro-
gen Corp., Carlsbad, CA, USA) was used to evaluate the in situ
formation of reactive oxygen species (ROS) using the method
described by Miller et al. [63]. Aortic rings (3–4 mm length) from
mice were embedded in OCT compound (Tissue Tek, Sakura,
Torrance, CA, USA) and frozen in a liquid nitrogen bath. These
unfixed frozen aortic rings were cut into sections (5 mm thick) and
placed on polylysine-coated plus glass slides. After defrosting at
room temperature for 60 min in a humidified chamber, DHE
(2 mM in PBS) was applied to each section, which was then
incubated in a light-protected humidified chamber at 37uC for
30 min before being mounted in Dako fluorescent mounting
medium (Dako North America Inc., CA, USA). Sections were kept
in the dark until fluorescence was determined using a confocal
microscope (LSM510 META Carl Zeiss Inc., Overkochen,
Germany). Quantification of the fluorescence intensity was
performed using ImageJ software (NIH, USA).
Immunofluorescent Staining
Frozen aortic rings embedded in OCT compound were
cryosectioned at 20 mm and fixed with 4% paraformaldehyde.
Fixed sections were incubated with antibodies directed against
either eNOS (1/100, BD Transduction Laboratories, San Jose,
CA, USA), NADPH oxidase subunits (p47phox and NOX-1, 1/
100, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
nitrotyrosine (1/100, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), cyclooxygenase-1 (COX-1, 1:200, Cayman Chemical
Co., Ann Arbor, MI, USA), cyclooxygenase-2 (COX-2, 1:200,
Cayman Chemical Co., Ann Arbor, MI, USA), Ang II (1:400,
Bachem, Bubendorf, Switzerland), or angiotensin type 1 receptor
(AT1R, 1:400, Peninsula Laboratories Inc., San Carlos, CA, USA)
overnight at 4uC. Immunoglobulin G coupled to Alexa 488 or 633
(Invitrogen Corp., Carlsbad, CA, USA) was used as secondary
antibody. The level of fluorescence in each section was examined
using a confocal microscope (LSM700 Carl Zeiss Inc., Over-
kochen, Germany). Images were analyzed by ImageJ software
(NIH, USA).
Measurement of Cyclooxygenase Activity
To determine the ability of LOE to inhibit COX-1 and/or
COX-2 activities, a COX inhibitor screening assay (kit 560131;
Cayman Chemical) was used according to the manufacturer’s
recommendation. The 96-well plate was read in an automated
microplate reader (VersaMax Plus) at 405 nm and the results were
calculated following the instructions.
Measurement of ACE Activity
Plasma ACE activity was measured by the rate of hydrolysis of
the synthetic tri-peptide substrate FAPGG to FAP using ACE
assay kits (Cat. #TR85056, TR85101, TR85201, Thermo Fisher
Scientific Inc., Middletown, VA, USA) as described previously
with some minor modifications [64]. 10 ml of ACE control,
calibrator or plasma was added to 100 ml of ACE reagent in a 96-
well micro-titer plate on ice, in triplicate. The reagents were
mixed, incubated at 37uC and absorbance at 340 nm was read at
1 min intervals. The average absorbance readings of ACE activity
in control, calibrator and plasma samples over time were plotted as
linear regression graphs and gradients of these linear regression
graphs DA/DT were calculated. The ACE activity of plasma
samples was obtained by comparison of DA/DT for each sample
with standards.
In vitro ACE activity was also assayed as described above with
some minor modifications. LOE was dissolved in HBSS.
Thereafter, 10 ml LOE or saline solution was added to 90 ml of
ACE reagent in a 96-well micro-titer plate on ice in a dose-
dependent manner, and the plate was mixed and incubated for
20 min. 10 ml of ACE control serum or saline was added to each
well. The reagents were mixed, incubated at 37uC and absorbance
at 340 nm was read at 1 min intervals for 5 min on an ELISA
micro-plate reader. All samples were assessed in triplicate. Data
were calculated as described above.
Determination of Physical Exercise Capacity
Two weeks before sacrifice, mice were trained for 5 min at
15 cm/sec once a day on the treadmill for three consecutive days.
Thereafter, the physical exercise capacity was assessed as the time
and distance to exhaustion. The condition for measurement was at
start 15 cm/sec and, thereafter, the speed was increased by 5 cm/
sec per 1 min with an intensity of 0.3 mA.
Chemicals
All chemicals were purchased from Sigma Chemical Co. unless
specified.
Statistical Analysis
Statistical analyses were performed using Student’s t test for
unpaired data to compare two treatments. In the case of pairwise
between-group comparisons, statistical analysis was carried out by
one-way analysis of variance (ANOVA) followed by the Tukey
post-hoc test. Concentration–response curves were compared by
two-way analysis of variance (ANOVA) followed by Bonferroni
post-hoc test. When the data consisted of repeated observations at
successive time points, repeated measures one-way ANOVA
followed by Tukey post-hoc test was applied to investigate
differences between groups. All statistical analyses were conducted
using Sigmaplot software (version 11) (SAS Institute, Cary, NC,
USA). All results are expressed as means6 SEM. Differences were
considered significant when P,0.05.
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